Abstract P2-09-12: Perilymphatic IRX-2 cytokine therapy to enhance tumor infiltrating lymphocytes (TILs) and PD-L1 expression preceding curative-intent therapy in early stage breast cancer (ESBC)
Pucilowska, J, Egan, JE, Berinstein, NL, Moxon, N, Aliabadi-Wahle, S, Imatani, JH, Conlin, A, Acheson, A, Massimino, K, Martel, M, Campbell, M, Wu, Y, Sun, Z, Redmond, W, Shah, M, Urba, WJ, Page, DB
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article
Abstract P2-09-03: Updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations with baseline lymphocyte and naïve CD4+ T-cell count
Page, DB, Pucilowska, J, Bennetts, L, Kim, I, Sanchez, K, Martel, M, Conlin, A, Moxon, N, Mellinger, S, Acheson, A, Kemmer, K, Mitri, Z, Vuky, J, Ahn, J, Abaya, C, Manigault, T, Basho, R, Urba, WJ, McArthur, HL
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article